ZURA vs. CHRS, IPHA, AGEN, ABOS, CMPX, GLUE, IVVD, INMB, MGX, and ADAP
Should you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Coherus BioSciences (CHRS), Innate Pharma (IPHA), Agenus (AGEN), Acumen Pharmaceuticals (ABOS), Compass Therapeutics (CMPX), Monte Rosa Therapeutics (GLUE), Invivyd (IVVD), INmune Bio (INMB), Metagenomi (MGX), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "biological products, except diagnostic" industry.
Coherus BioSciences (NASDAQ:CHRS) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, community ranking, dividends, analyst recommendations, profitability, earnings and valuation.
Coherus BioSciences received 426 more outperform votes than Zura Bio when rated by MarketBeat users. However, 100.00% of users gave Zura Bio an outperform vote while only 65.13% of users gave Coherus BioSciences an outperform vote.
72.8% of Coherus BioSciences shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 7.6% of Coherus BioSciences shares are held by company insiders. Comparatively, 15.8% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Zura Bio has a net margin of 0.00% compared to Zura Bio's net margin of -19.64%. Zura Bio's return on equity of 0.00% beat Coherus BioSciences' return on equity.
Coherus BioSciences presently has a consensus price target of $8.83, suggesting a potential upside of 361.27%. Zura Bio has a consensus price target of $18.83, suggesting a potential upside of 275.17%. Given Zura Bio's higher probable upside, equities analysts plainly believe Coherus BioSciences is more favorable than Zura Bio.
In the previous week, Coherus BioSciences had 1 more articles in the media than Zura Bio. MarketBeat recorded 9 mentions for Coherus BioSciences and 8 mentions for Zura Bio. Coherus BioSciences' average media sentiment score of 1.34 beat Zura Bio's score of 0.45 indicating that Zura Bio is being referred to more favorably in the news media.
Coherus BioSciences has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500.
Zura Bio has lower revenue, but higher earnings than Coherus BioSciences.
Summary
Coherus BioSciences beats Zura Bio on 8 of the 15 factors compared between the two stocks.
Get Zura Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zura Bio Competitors List
Related Companies and Tools
